Upstate Active Clinical Trials

Study Title:

Celldex Protocol CDX110-04: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma

What is the purpose of the study?

This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express the EGFRvIII protein) to the current standard of care (temozolomide) in patients with recently diagnosed glioblastoma, a type of brain cancer.

Upstate Institutional Review Board (IRB) Number:

290794

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Thomas E Coyle, MD

ClinicalTrials.Gov ID:

NCT01480479

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Diane M Gould
Phone: 315-464-8235
Email: gouldd@upstate.edu

Return to Previous Page || Search Again